At a Walmart somewhere in Texas, you can pick up a MELO Plus Melatonin Diffuser in Cotton Candy flavor — "like a carnival in a diffuser," the company's website promises, "sweet and fluffy spun sugar with hints of vanilla, caramel, and fruit" — for a few dollars. No prescription required. No pharmacist consultation. No proof of age.
You can also order it from Amazon. Or buy it at a gas station in South Carolina.
The device contains melatonin — the sleep hormone — suspended in vegetable glycerin and natural flavors, and is designed to be inhaled. The manufacturer, MELO Labs, says it contains no diacetyl and no vitamin E acetate. It does not say what independent laboratory confirmed this, because none has. No federal agency has reviewed the product for safety or efficacy. No clinical trial has established that inhaling melatonin through the lungs is safe, or that it even works as advertised.
This is not a niche regulatory edge case. Melatonin vapes — marketed variously as "diffusers," "inhalers," and "personal aroma devices" — are a growing industry with at least six active brands, candy-flavored product lines, and retail distribution at the nation's largest retailers. And they exist, according to a review of federal law and enforcement records, in a regulatory vacuum that the FDA has identified, acknowledged in official documents, and largely declined to close.
The Loophole That Built an Industry
The legal foundation for the melatonin vape market rests on a single word in a thirty-year-old law.
The Dietary Supplement Health and Education Act of 1994 — the legislation that exempts vitamins, herbal supplements, and products like melatonin gummies from FDA pre-market review — applies to products "intended for ingestion." Inhalation is not ingestion. This distinction is not a technicality discovered by clever lawyers after the fact; it is the explicit statutory language, and it means that melatonin vapes are, definitionally, not dietary supplements under federal law.
They are also not pharmaceutical drugs, because no company has submitted them for drug approval. They contain no nicotine, so the FDA's tobacco and e-cigarette regulatory frameworks do not apply. They are not food products. They are not medical devices.
What they are, legally, is essentially nothing — a consumer product category with no governing framework, no pre-market safety review, no mandatory adverse event reporting, and no requirement to list all ingredients on the label.
The industry, apparently, understood this from the beginning. The companies that sell melatonin vapes rarely call them "supplements." They use the language of wellness: "diffusers," "inhalers," "rapid onset formulas," products that "help regulate your sleep cycle." The FDA disclaimer — "These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease" — appears in fine print while the marketing promises faster, better, cleaner sleep.
What's Actually Inside
Last November, researchers at the University of North Carolina at Chapel Hill published a study in Chemical Research in Toxicology that may be the most unsettling document yet produced about this product category.
The study's lead author, Kevin D. Schichlein of UNC's Center for Environmental Medicine, Asthma, and Lung Biology, and colleagues analyzed the aerosol condensates of three commercially available melatonin vape devices and then exposed human bronchial epithelial cells — the cells lining the inside of the airway — to those aerosols at levels simulating 40 puffs.
The chemical analysis turned up contaminants that no consumer would expect to find in a sleep aid:
- Cyprodenate, a pharmaceutical stimulant
- Pivagabine, a pharmaceutical antidepressant
- Alloxydim, an herbicide used in agriculture
- Industrial chemicals used in the production of plastics, synthetic fibers, and filaments
- Cooling agents (menthol and WS-23) and an artificial sweetener (neotame) not disclosed on any label
None of these substances appeared on any product label. The study also found that 60 percent of the compounds identified in the aerosol condensates were unique to the aerosolized form — meaning they were not present in the liquid before heating, but were created by the act of vaporization. This is a known hazard of inhaled products: heating a substance transforms its chemistry in ways that neither the manufacturer nor the consumer may anticipate.
Perhaps most striking: one of the three devices tested "did not appear to contain melatonin, melatonin metabolites, or potential melatonin oxidation products" at all. A product marketed as a melatonin delivery device, containing no detectable melatonin.
The cellular effects were significant. Vape exposure altered the expression of 1,028 genes in the human airway cells — compared to just 183 genes for aqueous melatonin alone. The aerosols decreased the secretion of seven chemokines (signaling proteins that coordinate immune response), downregulated genes involved in inflammatory response and complement activation, and produced what the researchers called an "immunosuppressive gene expression signature." The lungs, in other words, appeared to become less capable of mounting a normal immune defense.
The study's authors were careful: they found no overt cytotoxicity (the cells did not die), and they called for further investigation rather than drawing conclusions about long-term human harm. But the finding that a $20 gas-station sleep device can suppress immune function in human lung tissue — while also containing an unlabeled antidepressant, a stimulant, and a pesticide — is not a finding designed to reassure.
A Dose Nobody Calculated
The contamination study emerged roughly six months after a separate pharmacokinetic analysis raised a different alarm about what happens when melatonin reaches the bloodstream via the lungs rather than the digestive tract.
A May 2024 study in Food and Chemical Toxicology, using physiologically-based pharmacokinetic modeling, calculated the plasma concentrations of melatonin produced by both oral and inhaled doses. The finding for inhaled melatonin was stark: a standard 2-milligram inhaled dose would produce plasma concentrations 645 times higher than the body's normal endogenous melatonin level. Even a standard oral dose of the same amount exceeded normal levels by 25-fold.
The researchers — whose affiliation with Philip Morris International's research division requires disclosure but does not negate the underlying mathematics of pharmacokinetic modeling — concluded that "inhaled caffeine and melatonin must be consumed with caution as the toxicological concerns are not known and could outweigh the potential beneficial effects."
This is significant for a specific reason. Melatonin's sleep-promoting effect depends on timing and dose — it works by signaling the brain's circadian clock that darkness has arrived. The dose that shifts the circadian clock is small; researchers have found that doses as low as 0.3 milligrams can be effective for circadian-related sleep problems. Flooding the system with 645 times normal levels does not produce 645 times the sleep benefit. It produces, potentially, circadian disruption — the opposite of the intended effect — along with whatever systemic effects haven't yet been studied because nobody has studied them.
Dr. Marc Sala, an assistant professor of pulmonology and critical care medicine at Northwestern University's Feinberg School of Medicine, put the dosing problem plainly. "When you take melatonin with a pill, it's reasonably accurate to dose," he told Sleep Review magazine. "Vaping is a far less accurate way of trying to dose medication." His bottom line on the category: "I personally would never recommend inhaling melatonin."
The Expert Consensus That the Industry Ignores
The scientists who study sleep, lungs, and toxicology have been saying versions of the same thing for years.
Dr. Philip Forys, a pulmonologist at Indiana University, noted that "melatonin is a large chemical compound, unlike nicotine and other commonly vaped substances," adding that "we really don't know if this is an efficient delivery mechanism, as there have been no studies conducted on the effects of vaping melatonin."
Dr. Michael Grandner, director of the Sleep and Health Research Program at the University of Arizona, was more blunt: "I have never heard of any research being done on melatonin and vaping."
Both doctors' comments date to earlier reporting on the category — meaning that when experts were first asked, years ago, whether melatonin vapes had any scientific foundation, the answer was no. The answer remains no today. There are currently two registered clinical trials investigating an inhaled melatonin formulation (NCT06801379 and NCT06802913) — but the fact that these trials are just now enrolling underscores the problem: consumer products have been on the open market for years while the basic clinical question of whether inhaled melatonin is safe or effective has not yet been answered.
Dr. Bonnie Halpern-Felsher, a professor of pediatrics at Stanford Medicine who has published extensively on non-nicotine vaping, frames the core issue in terms that apply to every product in this category: "The GRAS designation means something is safe to consume through eating, or as a salve on the skin, but that's very different from heating a substance and inhaling the resulting aerosol." Her research, published in JAMA Network Open in 2022, found that 26 percent of survey participants between ages 13 and 40 had tried non-nicotine vaping products; among 21-to-24-year-olds, the figure was 38 percent.
"We cannot continue to have non-nicotine vaping products on the open market for anybody to buy," she said, "especially given that young people are sharing them and don't know what they're using."
What EVALI Established — and What Was Forgotten
The year 2019 produced a public health crisis that should have answered, definitively, the question of whether food-safe ingredients are inhalation-safe ingredients.
EVALI — e-cigarette or vaping product use-associated lung injury — resulted in 2,807 confirmed hospitalizations and 68 deaths across all 50 states. The CDC identified the primary culprit as vitamin E acetate, a substance used in dietary supplements and skin care products, considered safe by the FDA for oral consumption. When inhaled through a vaporizer, it caused lipoid pneumonia: the accumulation of fat droplets in lung tissue, triggering inflammation, injury, and in dozens of cases, death.
The mechanism that killed EVALI patients — an oil that is safe to eat becoming dangerous when inhaled — applies directly to the carrier ingredients in melatonin vapes. Vegetable glycerin and propylene glycol, the most common bases for melatonin vape formulas, are GRAS for food use. A 2024 study in Scientific Reports found that aerosols from PG/VG mixtures disrupt mucociliary clearance — the lungs' primary self-cleaning mechanism — and produce airway inflammation and mucus hyperconcentration. Some formulations also incorporate MCT oil, which laboratory research has linked to exogenous lipoid pneumonia through the same basic pathway as vitamin E acetate.
"Many benign or beneficial compounds can become harmful if given in an untested way," wrote Aaron Scott and Alice Jasper, researchers in respiratory science at the University of Birmingham, in an analysis of wellness vapes. "Components like vegetable glycerin and propylene glycol break down when heated into harmful chemicals," including formaldehyde.
No confirmed EVALI cases specifically attributed to melatonin vapes have appeared in the published literature. This is likely a surveillance gap, not evidence of safety: there is no mandatory adverse event reporting for products in this regulatory category, no dedicated monitoring system, and no requirement for companies to track or disclose consumer health complaints.
The FDA's Track Record
The FDA has known that inhalable supplement vapes existed, and that they posed a regulatory problem, since at least 2020.
In December of that year, the agency issued a warning letter to a Florida company called NextL3vel Services Group marketing CBD vape products under the brand name "This Stuff Is Good For You." The letter's language on inhalation was unambiguous: "Because the ingredients and potential impurities in oral inhalation products may trigger laryngospasm and bronchospasm and may be toxic to the tissues in the upper or lower airways, you should be aware of the serious safety concern associated with this product."
A year later, in December 2021, the FDA sent a warning letter to NV Nutrition, LLC, the maker of the Nutrovape and Nutriair brands of inhalable supplements — products that had by then sold over two million devices in the United States, China, and more than ten other countries, generating an estimated $5 million in revenue. The letter cited the same safety concerns, nearly word for word.
Neither letter named Cloudy, Inhale Health, MELO Labs, or any of the brands currently dominating the melatonin vape market. A search of the FDA's publicly available enforcement records found no warning letters issued to those companies.
The pattern — warning letters to earlier-generation brands while current major brands operate without documented federal scrutiny — mirrors what Regan Bailey, a nutritional epidemiologist at Purdue University, described about the supplement vape category years ago: "These products might be completely safe, but they might not be. We know literally nothing about the safety or efficacy of inhaling vitamins."
In the absence of a specific regulatory framework, the FDA's primary lever is the Federal Food, Drug, and Cosmetic Act's prohibition on misbranded or adulterated products and on products making drug claims without approval. But the melatonin vape brands have become adept at threading this needle: their marketing implies sleep benefits strongly enough to drive sales while stopping just short of the explicit disease-treatment claims that would most clearly trigger enforcement. The FDA boilerplate disclaimer — fine print at the bottom of a product page — provides legal cover while the headline text promises "faster effects than pills or gummies."
Who Is Buying These Products
The industry's distribution strategy raises questions that go beyond individual consumer choice.
MELO Labs sells its products at Walmart, Amazon, and gas stations in Texas and South Carolina. Its flavor lineup — Cotton Candy, Blue Cloud (blue raspberry), Rainbow Road, Cosmic Berry, Peach Cream, Heaven — is indistinguishable in naming convention from the flavored nicotine vape products that state and federal regulators have spent years restricting specifically because of their appeal to minors.
"Like a carnival in a diffuser," the company's website says of its Cotton Candy flavor. The framing evokes nostalgia, not medicine. No pediatric safety warning appears on the product page. MELO Labs' website does not display an age verification gate.
This is not incidental. Federal regulators and researchers have established that flavor-naming strategy — candy, fruit, dessert names — is a primary mechanism through which nicotine vape companies attracted underage users. The same playbook, applied to a non-nicotine product in a regulatory category that no state has specifically addressed, is currently for sale in the candy aisle equivalent of the checkout line.
Pediatric melatonin poisonings offer relevant context. Accidental ingestions of melatonin by children rose from roughly 8,000 cases in 2012 to more than 52,000 in 2021 — a 550 percent increase driven largely by gummies that resemble candy. Vaping a flavored sleep product presents a different risk profile than eating an overdose of gummies, but the underlying dynamic — a substance associated with medicine becoming available in forms that blur the line between supplement and treat — is the same one that produced the pediatric poisoning crisis.
Inhale Health, one of the oldest brands in the category, markets its product as a "rapid onset formula" with claims of bioavailability superiority over pills. Its CEO, Daniel Wolf Shapiro, told Rolling Stone that "less melatonin is necessary to take effect as it's instantly absorbed, allowing consumers to use as they go, and take only what they need." The claim of instant absorption has no published clinical support. The suggestion that inhaled dosing allows users to "take only what they need" runs directly counter to the pharmacokinetic modeling showing that a standard inhaled dose produces plasma concentrations orders of magnitude higher than oral administration.
The Precedent That Exists and Isn't Being Used
When the FDA decided to act against caffeinated alcoholic beverages in 2010, it moved with speed and specificity. The agency issued formal determinations that caffeine was an unsafe food additive in alcoholic malt beverages, sent warning letters with 15-day compliance deadlines, and the brands reformulated within days. The legal mechanism was the FD&C Act's food additive authority — a different provision than DSHEA, and one that the FDA has available to apply to inhalable products as well.
The agency has already, in a separate regulatory context, determined that melatonin cannot be added to conventional foods because it lacks food additive authorization and is not GRAS for food use. Whether that reasoning extends to an argument that melatonin is an unsafe additive when present in an inhalable product has not been tested. Legal scholars who have examined DSHEA's scope have noted that the "ingestion" definition was not intended to create a category of unregulated inhalable health products — it was intended to cover the normal delivery of supplements by swallowing them. The gap is a legislative accident, not a deliberate policy choice.
The FTC's updated Health Products Compliance Guidance, issued in December 2022, requires that health claims be substantiated by "competent and reliable scientific evidence" — in practice, randomized controlled trials. No such trials exist for inhaled melatonin. The FTC sent penalty notices to 670 health-product companies in April 2023 warning that unsubstantiated claims would be subject to civil penalties. Whether any of those notices went to melatonin vape companies is not publicly known; the agency has not announced any enforcement actions in the category.
Congress has not introduced any legislation addressing non-nicotine supplement vapes as a distinct product category. Existing legislative attention to vaping focuses on nicotine and tobacco products.
What Would It Take to Know If These Are Safe?
The answer to whether melatonin vapes are safe to inhale regularly is not available — not because the answer is unknowable, but because nobody has funded or conducted the research required to produce it.
Establishing safety would require, at minimum: randomized controlled trials measuring pulmonary function in users over time; pharmacokinetic studies in humans confirming plasma concentrations and clearance rates; toxicological studies on the specific aerosol compositions of specific commercial products; and long-term epidemiological data on respiratory outcomes in users. Establishing efficacy for sleep would require separate randomized trials comparing inhaled melatonin to placebo and to oral melatonin under controlled conditions.
None of these studies exist. The two clinical trials currently registered on ClinicalTrials.gov investigating inhaled melatonin as a pharmaceutical formulation have not yet reported results. The consumer products are already in gas stations, on Amazon, and at Walmart.
"We really need toxicologists and other scientists to help us understand what these chemicals are doing to our bodies," Dr. Halpern-Felsher said. "Anything you're vaping — anything you're buying without a prescription, heating and inhaling — is bad for your lungs."
The melatonin vape industry has a different answer. Its products come with FDA disclaimers, candy-flavored packaging, and cotton-candy promises. What they don't come with is evidence.
This article is based on peer-reviewed research, FDA enforcement documents, and publicly available expert commentary. The 2024 contamination study (Schichlein et al.) did not identify the specific brands it tested by name; findings about contamination apply to commercially available products as a category. The pharmacokinetic modeling study (Kolli et al.) was authored by researchers affiliated with Philip Morris International; the underlying modeling methodology is standard in pharmaceutical research.
